25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study
Grant A. McArthur(The University of Melbourne), A. Ribas, Claus Garbe(University Children's Hospital Tübingen), Brigitte Dréno(Inserm), Lev Demidov(Heidelberg University), Luis de la Cruz‐Merino, Michele Maio(University of Siena), Daniel O. Koralek, Linzi Thomas, Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Matthew Wongchenko, Y. Yan, Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Daniil Stroyakovskiy(Shikoku Cancer Center), James Larkin(Trinity College Dublin), Victoria Atkinson(The University of Queensland), Jessie J. Hsu, Mario Mandal�, G. Liszkay, Isabelle Rooney
Cited by 10
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2019|3.7k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k